A federal judge denied BioDelivery Sciences International Inc.’s attempt to use a 2022 patent-infringement judgment against Lotus Pharmaceutical Co.’s Alvogen units to stop a new generic version of the painkiller Belbuca, ruling BDSI used the wrong legal tool to enforce that injunction.
BDSI can’t use a routine motion to police compliance with a permanent injunction and instead must seek to have Alvogen held in contempt of court, Chief Judge Colm F. Connolly wrote in an opinion issued Monday in the US District Court for the District of Delaware. Connolly didn’t address whether Alvogen’s new copies of the opioid film infringe, ...